Testing for latent tuberculosis before starting patients on immune checkpoint inhibitors

Dhar, Chirag

doi:10.4103/ijc.ijc_283_20

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer immunotherapy is a relatively new and promising treatment modality that has emerged in recent years [81]. Although this therapy can yield positive clinical outcomes, further research is needed to determine its efficacy in patients with concurrent PTB [82][83][84]. Therefore, a systematic and detailed understanding of the immunological mechanisms in LC-PTB can contribute to developing immunotherapeutic approaches for these comorbidities, representing a new research focus in the field.…”

Section: Analysis Of Research Trends and Frontiersmentioning

confidence: 99%

Visualization analysis of research progress and trends in coexistence of lung cancer and pulmonary tuberculosis using bibliometrics

Yang,

Ye,

et al. 2024

Medicine Advances

View full text Add to dashboard Cite

BackgroundThe incidence of lung cancer combined with pulmonary tuberculosis has been increasing, but there is relatively limited published literature on the topic of lung cancer combined with tuberculosis (LC‐PTB) from a bibliometric perspective. Therefore, in this study, we aimed to quantitatively analyze the LC‐PTB‐related literature to better understand the current status of this field and identify future research trends.MethodsWe searched for articles related to LC‐PTB using the Web of Science Core Collection (SCI‐E) and conducted a visual analysis of publication quantity, countries, institutions, authors, journals, references, and keywords using bibliometric software (CiteSpace, VOSviewer, and Scimago Graphica).ResultsAs of January 8, 2024, a total of 460 publications related to LC‐PTB were included for analysis from 3705 retrieved records. The number of publications has been increasing almost yearly, with most from China (n = 123), followed by the United States (n = 77). Taipei Medical University contributed the most publications (n = 11). Jing‐Yang Huang and Yung‐Po Liaw (eight documents each) ranked first among the included authors. The Journal of Thoracic Oncology was the most productive academic journal on LC‐PTB. The aggregation of key nodes in the co‐citation network and the chronological sequence indicated that LC‐PTB research has shifted from initial hotspots such as lung diseases, bronchitis, and exposure to recent areas, including immunotherapy, immune checkpoint inhibitors, and nivolumab.ConclusionIn this study, we visualized the current status of LC‐PTB research as well as future trends using bibliometric methods, providing new insights into the differential diagnosis of LC‐PTB and its related promoting mechanisms.

show abstract